^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    STAT5A (Signal Transducer And Activator Of Transcription 5A)

    i
    Other names: STAT5A, Signal Transducer And Activator Of Transcription 5A, STAT5, MGF, Epididymis Secretory Sperm Binding Protein
    1d
    Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. (PubMed, Cell Rep Med)
    Mechanistically, PD-1/IL-2 bsAb-driven STAT5 activation transcriptionally upregulates CD47 on CD8+ T cells, which shields them from macrophage-mediated phagocytosis and enhances T cell survival in the tumor microenvironment. These findings delineate a role for the IL-2-STAT5-CD47 axis in immune evasion and suggest reactivating this pathway with PD-1/IL-2 bsAb may represent a therapeutic strategy to overcome resistance in this subtype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    IL2RA expression
    1m
    The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity. (PubMed, Antib Ther)
    All four components (anti-NKp46, Fc, IL15v, anti-tumor-associated antigen) of IL15v-NKCE are essential for maximal activity, and IL15v-NKCE is more potent than the conventional NKCE when combined with anti-PD-1 in preclinical models. By integrating IL15v into our anti-NKp46 based NKCEs, IL15v-NKCE has exhibited enhanced anti-tumor efficacy while maintaining an acceptable safety profile, thereby positioning it as a promising next-generation therapeutic modality for NK cell-based therapy.
    Journal
    |
    IL15 (Interleukin 15) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    1m
    Regulation and Mechanism of Deleted in Breast Cancer-1 on Dendritic Cell Function in Systemic Lupus Erythematosus. (PubMed, MedComm (2020))
    With STAT5 overexpression, the protective effect by Dbc1-/- DC was abolished in the lupus model. Therefore, targeting the DBC1-STAT5 axis in DCs diversifies the therapeutic strategies for SLE.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • IL4 (Interleukin 4) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    PD-L1 expression
    2ms
    Hypoxia promotes progression of cervical cancer by modulating the ATXN3-enhanced P53 stability or STAT5 phosphorylation. (PubMed, Cell Death Discov)
    ATXN3 overexpression stabilized P53 in C33A/HeLa and increased p-STAT5 in SiHa, with inverse effects upon silencing. The findings suggest that hypoxia promotes the progression of subtypes of cervical cancer by regulating ATXN3-enhanced P53/p-STAT5 levels, which may provide a novel therapeutic strategy for clinical applications.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • ATXN3 (Ataxin 3)
    2ms
    Single Nucleus MultiOmics Links Novel Transcription Factor Motifs to Murine Hepatic Sex Differences in Chromatin Accessibility and Metabolic Dysfunction-Associated Steatotic Liver Disease. (PubMed, bioRxiv)
    We also identified stringently cell type-specific regulatory regions with cell type-specific TF motifs that define the regulatory architecture underlying hepatocyte and non-parenchymal cell identities. This comprehensive multiOmic atlas elucidates TF networks controlling sex-dependent liver gene expression and serves as a foundational resource for understanding molecular mechanisms underlying sex disparities in MASLD and other liver diseases.
    Preclinical • Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    2ms
    Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC). (PubMed, J Cancer Res Clin Oncol)
    Overall, these findings demonstrate the ability of BPP to influence dendritic and T-cell responses in NSCLC via coordinated transcriptional and chromatinremodelling activities.
    Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL10 (Interleukin 10) • HDAC2 (Histone deacetylase 2) • TBX21 (T-Box Transcription Factor 21) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • STAT2 (Signal transducer and activator of transcription 2) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • CD1D (CD1d Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    2ms
    Safety and Efficacy of PMT Therapy of hPAP (clinicaltrials.gov)
    P1/2, N=3, Recruiting, Children's Hospital Medical Center, Cincinnati | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial primary completion date • First-in-human
    |
    CSF2 (Colony stimulating factor 2) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    2ms
    Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies. (PubMed, Signal Transduct Target Ther)
    These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    3ms
    Targeting STAT5 Attenuates Retinal Neovascularization by Promoting Apoptosis and Suppressing Endothelial Cell Function. (PubMed, Exp Eye Res)
    Furthermore, the proliferation, migration, invasion, and tube-forming capacities of HRMVECs were significantly suppressed following treatment with the STAT5 inhibitor. Our findings demonstrate that STAT5 signaling promotes RNV progression by enhancing endothelial cell survival and angiogenic functions.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    3ms
    Non-alcoholic fatty pancreas disease (NAFPD) as a pre-neoplastic niche: Metabolic and inflammatory Gateways to pancreatic ductal adenocarcinoma. (PubMed, J Clin Transl Endocrinol)
    Lipid-laden stellate cells promote fibrosis, immunosuppression, and epithelial-mesenchymal transition. NAFPD may represent an early, modifiable PDAC niche, warranting further imaging-omic studies and targeted prevention trials.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    KRAS G12D • KRAS G12
    3ms
    The Prognostic Role of STAT5B Across Cancer Types and Comparative Analysis with STAT5A: A Systematic Review. (PubMed, Biomolecules)
    Elevated STAT5B expression is associated with improved survival in multiple cancers, supporting a potential tumor-suppressive role distinct from STAT5A. These findings underscore the importance of isoform-specific STAT5 evaluation in cancer prognosis and suggest that STAT5B may serve as a potential biomarker and therapeutic target.
    Clinical • Review • Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    3ms
    IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer. (PubMed, bioRxiv)
    Pharmacological inhibition of IRG1 reverses these effects, restoring PARPi sensitivity and enhancing anti-tumor immunity in BRCA1-deficient tumor models. Collectively, these findings uncover a TAM-specific immunometabolic program that limits PARPi efficacy and highlight the IRG1/NRF2/GSH axis as a promising therapeutic target to improve treatment outcomes in BRCA1-associated breast cancer.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • STING (stimulator of interferon response cGAMP interactor 1) • STAT5A (Signal Transducer And Activator Of Transcription 5A)